Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 9040 results

  1. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

    Safe staffing guideline
    Discontinued

  2. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

    Safe staffing guideline
    Discontinued

  3. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  5. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  6. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    Discontinued Reference number: GID-TA11647

    Technology appraisal guidance
    Discontinued

  7. Suspected cancer (QS124)

    April 2026: We have withdrawn this quality standard following the launch of the updated NICE guideline on suspected cancer: recognition and referral. An updated NICE quality standard for suspected cancer is being developed.  For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  8. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    In development Reference number: GID-TA11655 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE HealthTech guidance 733.

    Withdrawn guidance

  12. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  13. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  15. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued Reference number: GID-TA11259

    Technology appraisal guidance
    Discontinued